e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The risk of community-acquired pneumonia in children using gastric acid suppressants
Linda J.T.M. van der Sande, Quirijn Jöbsis, Michiel A.G.E. Bannier, Ewoudt M.W. van de Garde, Jan J.M. Coremans, Frank de Vries, Edward Dompeling, Johanna H.M. Driessen
Source:
Eur Respir J, 58 (4) 2003229; 10.1183/13993003.03229-2020
Journal Issue:
October
Disease area:
Paediatric lung diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Linda J.T.M. van der Sande, Quirijn Jöbsis, Michiel A.G.E. Bannier, Ewoudt M.W. van de Garde, Jan J.M. Coremans, Frank de Vries, Edward Dompeling, Johanna H.M. Driessen. The risk of community-acquired pneumonia in children using gastric acid suppressants. Eur Respir J, 58 (4) 2003229; 10.1183/13993003.03229-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
ERS statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials
Related content which might interest you:
The risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants
Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis
Year: 2008
Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Risk factors of community-acquired pneumonia in children
Source: Eur Respir J 2010; 36: 1221-1222
Year: 2010
The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010
Oropharyngeal dysphagia is a risk factor for community-acquired pneumonia in the elderly
Source: Eur Respir J 2013; 41: 923-928
Year: 2013
Inhaled drugs as risk factors for community-acquired pneumonia
Source: Eur Respir J 2010; 36: 1080-1087
Year: 2010
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Peculiarities of community-acquired pneumonia in tobacco-smoking patients
Source: Annual Congress 2009 - Tobacco: from smoke to disease
Year: 2009
Mixed community-acquired pneumonia in hospitalised patients
Source: Eur Respir J 2006; 27: 795-800
Year: 2006
Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Inhaled drugs as risk factors for community-acquired pneumonia
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010
Predisposing factors for bacteremia in patients with community-acquired pneumonia and positive pneumococcal urinary antigen
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Risk factors for drug-resistant pathogens in patients with hospital-acquired and ventilator-associated pneumonia
Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes
Year: 2017
Oral antibiotics prior to hospitalisation for community-acquired pneumonia
Source: Eur Respir J 2008; 31: 478-479
Year: 2008
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients
Source: Eur Respir J 2015; 45: 463-472
Year: 2015
Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020
Impact of aspiration pneumonia in community-acquired pneumonia and healthcare-associated pneumonia
Source: Annual Congress 2012 - CT findings: educational posters
Year: 2012
Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients
Source: Eur Respir J 2003; 22: 77S-83S
Year: 2003
The etiological agents of community-acquired pneumonia in our hospital
Source: Eur Respir J 2006; 28: Suppl. 50, 735s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept